Kaiser Permanente Ventures

With $7 billion of committed capital, IVP is one of the premier later-stage venture capital and growth equity firms in the United States. IVP is a hard-working team of experienced investors who have advised a large number of technology executives over the past few decades. We are a dedicated group of investment professionals who specialize in later-stage company growth, typically companies above $100 million valuation. Growth is our doctrine: we truly believe it is the key catalyst that separates the ultimate winners from the rest of the pack. We know that it takes persistence, experience, vision, and agility to achieve true greatness. Our firm works hard to help CEOs mitigate the daunting risks and challenges that inevitably appear during the rapid growth phases of a company's life. We hope we get to be a part of your journey as a growth company. IVP was founded by Reid Dennis in 1980. Since then, IVP has invested in over 300 companies, 106 of which have gone public. IVP is one of the top-performing firms in the industry and has a 36-year IRR of 43.2%.

Foundry Group is a Colorado-based venture firm that invests in early-stage and growth-stage companies headquartered in the US and Canada. Foundry Group also invests in select, newly-formed venture capital fund managers. Foundry Group formed in 2007 and originally focused on Seed and Series A investments. It raised a growth-stage fund in 2014 (Foundry Group Next), and a fund dedicated to investing in other venture funds (Foundry Group Next) in 2016. Regardless of the size of our initial investment, the size and structure of our funds allow us to continue to fund portfolio companies through their entire financing lifecycles. In addition, our venture capital fund investments give us insight and access to a large number of venture-backed companies at varying stages while extending the reach of our overall network. In addition to providing capital, we leverage our experience in starting and growing companies, our expertise in the technology industry, and our network of relationships to help outstanding entrepreneurs and venture capital fund managers turn great ideas into great companies.

Venrock is a venture capital firm headquartered in Palo Alto that focuses on disruptive early-stage technology startups. Venrock partners with entrepreneurs who have grand ambitions and want to tackle big, hard problems that most think impossible. Venrock today consists of two separate programs: a traditional venture capital program, focused on early stage investing in healthcare and technology companies; and a later-stage healthcare program, which implements a venture capital-like long-term approach to investment opportunities in small capitalization public companies and late-stage private healthcare companies. Venrock was formed in 1969 as a venture arm of the Rockefeller family (the name Venrock being a compound of Venture and Rockefeller), who have a long history of venture-style investing dating back to the early 20th century.

Canaan Partners is an early-stage venture capital firm investing in technology and healthcare companies in the United States.

Edison Partners is a growth-stage venture capital firm based in Princeton, NJ that invests in technology-enabled companies in the Eastern United States. Edison focuses its investments on three areas in which it has deep exertise: Fintech, Healthcare IT and Enterprise Solutions. We have made more than 200 investments and exited more than 170 companies over a history spanning more than 30 years. Edison supports management teams with our industry, investing and operating expertise and access to our Edison Edge platform. We have seen the movie many times before, assist in avoiding pitfalls that are not obvious to less experienced investors, and bring an array of prior successful exits with roadmaps to get there.

New Leaf Venture Partners is an early and growth-stage investor exclusively focused on healthcare technology. We invest across four sectors of healthcare technology: biopharmaceuticals, information convergence, medical devices and life science tools. In Biopharmaceuticals we invest from seed (creation) stage through to IPO and beyond. We look for large unmet medical needs, strong science, well differentiated technologies, and high-quality pre-clinical and clinical development programs. In Information Convergence (which includes healthcare IT, tools and diagnostics) we invest from early stages through to companies with revenues of $100m+. We have a similar approach in Medical Devices (where we look for important medical devices with the power to reduce costs and improve efficiencies in the healthcare system) and Life Sciences (where we look for products that accelerate the discovery process, uncover novel insights into the biology of disease and health, and personalize diagnoses and treatment).